V. A. Morrison

5.3k total citations · 1 hit paper
26 papers, 1.9k citations indexed

About

V. A. Morrison is a scholar working on Pathology and Forensic Medicine, Infectious Diseases and Epidemiology. According to data from OpenAlex, V. A. Morrison has authored 26 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pathology and Forensic Medicine, 9 papers in Infectious Diseases and 9 papers in Epidemiology. Recurrent topics in V. A. Morrison's work include Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Antifungal resistance and susceptibility (7 papers). V. A. Morrison is often cited by papers focused on Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Antifungal resistance and susceptibility (7 papers). V. A. Morrison collaborates with scholars based in United States, United Kingdom and Austria. V. A. Morrison's co-authors include D. A. Stevens, Punit D. Wadhwa, Thomas F. Patterson, Stephen Dummer, John E. Bennett, V L Kan, Thomas J. Walsh, David W. Denning, Marc A. Judson and George A. Pankey and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Infectious Diseases.

In The Last Decade

V. A. Morrison

26 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Practice Guidelines for Diseases Caused by Aspergillus

2000 581 citations D. A. Stevens, V L Kan et al. Clinical Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V. A. Morrison United States	14	1.2k	1.0k	291	236	216	26	1.9k
Luana Fianchi Italy	28	687 0.6×	772 0.7×	565 1.9×	136 0.6×	122 0.6×	91	2.3k
Helen Leather United States	23	1.1k 0.9×	1.1k 1.1×	641 2.2×	72 0.3×	162 0.8×	49	2.3k
Gerda Silling Germany	27	903 0.7×	920 0.9×	587 2.0×	83 0.4×	126 0.6×	49	1.8k
Jo‐Anne H. van Burik United States	19	930 0.8×	1.1k 1.1×	473 1.6×	52 0.2×	112 0.5×	24	1.9k
Anne Thiébaut France	21	1.4k 1.2×	1.4k 1.3×	436 1.5×	34 0.1×	172 0.8×	42	2.1k
Zdeněk Ráčil Czechia	20	868 0.7×	762 0.7×	245 0.8×	40 0.2×	98 0.5×	81	1.7k
Z. Erjavec Netherlands	16	1.9k 1.5×	1.8k 1.7×	648 2.2×	55 0.2×	377 1.7×	24	2.5k
Masahiko Okudaira Japan	18	589 0.5×	1.0k 1.0×	333 1.1×	99 0.4×	180 0.8×	105	1.9k
Ľuboš Drgoňa Slovakia	17	636 0.5×	574 0.6×	403 1.4×	60 0.3×	181 0.8×	53	1.4k
Annamaria Nosari Italy	21	813 0.7×	898 0.9×	960 3.3×	241 1.0×	135 0.6×	52	2.0k

Countries citing papers authored by V. A. Morrison

Since Specialization

Citations

This map shows the geographic impact of V. A. Morrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. A. Morrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. A. Morrison more than expected).

Fields of papers citing papers by V. A. Morrison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. A. Morrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. A. Morrison. The network helps show where V. A. Morrison may publish in the future.

Co-authorship network of co-authors of V. A. Morrison

This figure shows the co-authorship network connecting the top 25 collaborators of V. A. Morrison. A scholar is included among the top collaborators of V. A. Morrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. A. Morrison. V. A. Morrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Eichhorst, Barbara, Marije E. Hamaker, Kamil Kaplanov, et al.. (2016). Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Annals of Oncology. 28(2). 218–227. 55 indexed citations

2.

Morrison, V. A., Paul A. Hamlin, Pierre Soubeyran, et al.. (2015). Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. Annals of Oncology. 26(6). 1058–1068. 50 indexed citations

3.

Hong, Fangxin, Thomas M. Habermann, Leo I. Gordon, et al.. (2014). The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Annals of Oncology. 25(3). 669–674. 38 indexed citations

4.

Kauffman, Carol A., Alison G. Freifeld, David R. Andes, et al.. (2014). Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant‐Associated Infection Surveillance Network (TRANSNET). Transplant Infectious Disease. 16(2). 213–224. 108 indexed citations

5.

Goon, Peter, V. A. Morrison, Nicola Fearnhead, et al.. (2013). High resolution anoscopy may be useful in achieving reductions in anal cancer local disease failure rates. European Journal of Cancer Care. 24(3). 411–416. 6 indexed citations

6.

Morrison, V. A., et al.. (2011). A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501).. Journal of Clinical Oncology. 29(15_suppl). TPS223–TPS223. 2 indexed citations

7.

Morrison, V. A., Jeffrey L. Johnson, Sungwon Jung, John P. Leonard, & Bruce D. Cheson. (2010). A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis.. Journal of Clinical Oncology. 28(15_suppl). 8106–8106. 5 indexed citations

8.

Blaes, Anne, Winston Cavert, & V. A. Morrison. (2009). Malassezia: is it a pulmonary pathogen in the stem cell transplant population?. Transplant Infectious Disease. 11(4). 313–317. 7 indexed citations

9.

Ostrosky‐Zeichner, Luis, Carole A. Sable, Jack D. Sobel, et al.. (2007). Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. European Journal of Clinical Microbiology & Infectious Diseases. 26(4). 271–276. 275 indexed citations

10.

Morrison, V. A., Edie Weller, Thomas M. Habermann, et al.. (2007). Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 update. Journal of Clinical Oncology. 25(18_suppl). 8011–8011. 14 indexed citations

11.

Wadhwa, Punit D. & V. A. Morrison. (2006). Infectious Complications of Chronic Lymphocytic Leukemia. Seminars in Oncology. 33(2). 240–249. 152 indexed citations

12.

Habermann, Thomas M., Edie Weller, V. A. Morrison, et al.. (2004). Rituximab-CHOP Versus CHOP with or without Maintenance Rituximab in Patients 60 Years of Age or Older with Diffuse Large B-Cell Lymphoma (DLBCL): An Update.. Blood. 104(11). 127–127. 42 indexed citations

13.

Morrison, V. A., Vincent Caggiano, Moshe Fridman, & David J. Delgado. (2004). A model to predict chemotherapy-related severe or febrile neutropenia in cycle one among breast cancer and lymphoma patients. Journal of Clinical Oncology. 22(14_suppl). 8068–8068. 7 indexed citations

14.

Morrison, V. A., Vincent Caggiano, Moshe Fridman, & David J. Delgado. (2004). A model to predict chemotherapy-related severe or febrile neutropenia in cycle one among breast cancer and lymphoma patients. Journal of Clinical Oncology. 22(14_suppl). 8068–8068. 10 indexed citations

15.

Morrison, V. A.. (2002). Introduction: Infections in patients with hematologic malignancies and bone marrow transplantation-A changing and diverse spectrum. 17(2). 89–90. 1 indexed citations

16.

Perfect, John R., G. M. Cox, Carol A. Kauffman, et al.. (2001). The Impact of Culture Isolation ofAspergillusSpecies: A Hospital‐Based Survey of Aspergillosis. Clinical Infectious Diseases. 33(11). 1824–1833. 350 indexed citations

17.

Stevens, D. A., V L Kan, Marc A. Judson, et al.. (2000). Practice Guidelines for Diseases Caused by Aspergillus. Clinical Infectious Diseases. 30(4). 696–709. 581 indexed citations breakdown →

18.

Morrison, V. A. & DJ Weisdorf. (2000). The spectrum of Malassezia infections in the bone marrow transplant population. Bone Marrow Transplantation. 26(6). 645–648. 37 indexed citations

19.

Morrison, V. A.. (1994). Chronic leukemias. CA A Cancer Journal for Clinicians. 44(6). 353–377. 12 indexed citations

20.

Morrison, V. A. & Daniel J. Weisdorf. (1993). Alternaria: A Sinonasal Pathogen of Immunocompromised Hosts. Clinical Infectious Diseases. 16(2). 265–270. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact